H. pylori Diagnosis: Selecting the Appropriate Testing Methodology
Title: H. pylori Diagnosis: Selecting the Appropriate Testing Methodology
Originally Aired: Wednesday, December 5, 2018
Time: 1:00 p.m. ET
Presenter: David Lyerly, PhD
Unless otherwise noted, P.A.C.E.™ accreditation will expire six months after the live webinar.
What to Consider When Comparing Tests
In the United States, 20% of the population under 30 years of age and 50% of the population over 60 is infected with Helicobacter pylori. On a larger scale, it’s estimated that half of the global population is infected with H. pylori. These infections may be asymptomatic, but can lead to dyspepsia or serious complications such as duodenal and gastric ulcers, an increased risk of gastric cancer, and higher rates of mucosal-associated lymphoid-type lymphoma.
Several invasive and non-invasive methodologies are currently available for diagnosing an H. pylori infection both before and after eradication therapy. Each testing methodology poses advantages and disadvantages for the laboratory, patient, and institution. In this P.A.C.E.-accredited Fisher Healthcare webinar, David Lyerly, PhD, will discuss the bacteria, disease state, and guidelines for diagnosing H. pylori infections. He will also discuss how to select the appropriate testing methodology by balancing performance, economics, workflow, and patient care.
This webinar will help you:
- Discuss appropriate patient care within a test-treat-test framework while also considering economics and convenience
- Examine ways to protect the financial health and reputation of the institution while providing the best patient care
- Choose an appropriate testing methodology by balancing performance, economics, and workflow
This webinar is produced by Whitehat Communications, a provider of continuing education programs in clinical laboratory sciences that has been approved by the ASCLS P.A.C.E. Program. One P.A.C.E. credit hour will be provided for this complimentary, basic-level program.
David Lyerly, PhD
Dr. Lyerly has published more than 120 peer-reviewed publications on intestinal disease. He is a frequent invited speaker at regional, national, and international meetings and an invited reviewer for numerous journals and committees. He received his PhD from Wake Forest University and was a research scientist at the Anaerobe Laboratory at Virginia Tech. He is a co-founder and the Chief Scientific Officer of TechLab.